Search Result

Results for "

and CDK2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AAK1 (2) Akt (5) AMPK (3) Anaplastic lymphoma kinase (ALK) (3) Androgen Receptor (2) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (67) ATM/ATR (1) Aurora Kinase (2) Autophagy (9) Bacterial (1) Bcl-2 Family (4) c-Kit (1) c-Myc (1) Calcium Channel (1) CaMK (1) Carbonic Anhydrase (5) Casein Kinase (1) Caspase (7) CDK (260) CFTR (1) Checkpoint Kinase (Chk) (2) Cholinesterase (ChE) (1) COX (1) CXCR (2) Cyclin G-associated Kinase (GAK) (1) DNA/RNA Synthesis (2) Drug Isomer (1) E3 Ligase Ligand-Linker Conjugates (2) EGFR (13) Endogenous Metabolite (1) Enterovirus (1) Ephrin Receptor (1) ERK (2) FAK (2) FGFR (2) FLT3 (6) Fungal (2) GSK-3 (20) HDAC (2) Heme Oxygenase (HO) (1) HIV (2) IKK (1) Interleukin Related (3) IRAK (1) Isotope-Labeled Compounds (3) Itk (1) JAK (6) JNK (3) Keap1-Nrf2 (2) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (3) LIM Kinase (LIMK) (1) MAP4K (1) MAPKAPK2 (MK2) (2) MDM-2/p53 (1) MEK (2) MELK (1) Microtubule/Tubulin (2) Mitochondrial Metabolism (1) Molecular Glues (9) mTOR (2) MyD88 (1) Necroptosis (2) NEKs (1) NF-κB (1) P-glycoprotein (1) p38 MAPK (2) Parasite (1) PARP (2) PDGFR (1) Phosphatase (1) Phosphodiesterase (PDE) (2) PI3K (7) Pim (4) PKA (1) PKC (7) PKD (1) PROTAC Linkers (3) PROTACs (10) PSMA (2) Reactive Oxygen Species (ROS) (4) Reference Standards (7) Reverse Transcriptase (1) ROS Kinase (1) Salt-inducible Kinase (SIK) (1) SARS-CoV (1) Ser/Thr Kinase (2) Sirtuin (1) Small Interfering RNA (siRNA) (7) SphK (1) Src (4) STAT (4) Survivin (1) Telomerase (1) Toll-like Receptor (TLR) (1) Topoisomerase (2) Trk Receptor (2) ULK (1) VEGFR (10) Wee1 (4)
By Research Areas:	Cancer (269) Cardiovascular Disease (3) Infection (6) Inflammation/Immunology (15) Metabolic Disease (4) Neurological Disease (20)
Click Chemistry:	Alkynes (2)
Oligonucleotides:	Rat Pre-designed siRNA Sets (2) Mouse Pre-designed siRNA Sets (2) Human Pre-designed siRNA Sets (3) siRNAs (7)

298

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Targets Recommended: Fat Mass and Obesity-associated Protein (FTO)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-163814

CDK2 degrader 1	Molecular Glues CDK	Cancer
CDK2 degrader 1 (Compound 3) is a selective CDK2 molecular glue degrader with a D_max (CDK2) of > 80% and a K_i (CRBN) > 1 μM. CDK2 degrader 1 binds to cereblon to induce ubiquitination and subsequent proteasomal degradation of the CDK2. CDK2 degrader 1 is used in the research of a wide range of cancers .

HY-162255

CDK2-IN-23	CDK	Cancer
CDK2-IN-23 (Compound 17) is a kinase selective and highly potent *CDK2* inhibitor (IC₅₀ = 0.29 nM). CDK2-IN-23 shows the pharmacodynamic inhibition of CDK2 in CCNE1-amplified mouse models. CDK2-IN-23 can be used for the research of cancer .

HY-164664

CDK2-IN-30	CDK	Cancer
CDK2-IN-30 (Formula (I)) is a *CDK2* inhibitor with an IC₅₀ value ≤20 nM. CDK2-IN-30 can be used in tumor research .

HY-W478102

CDK2-IN-13	CDK	Cancer
CDK2-IN-13 (Compound 15) is a *CDK2* inhibitor with an IC₅₀ of 12 µM. CDK2-IN-13 can be used in research of cancer .

HY-143497

*HDAC1/2 and* CDK2-IN-1**	HDAC CDK Apoptosis	Cancer
HDAC1/2 and CDK2-IN-1 (compound 14d) is a potent HDAC1, HDAC2 and *CDK2* dual inhibitor, with IC₅₀ values of 70.7, 23.1 and 0.80 μM, respectively. HDAC1/2 and CDK2-IN-1 can block the cell cycle and induce apoptosis. HDAC1/2 and CDK2-IN-1 exhibits desirable in vivo antitumor activity .

HY-W478102S

CDK2-IN-13-d3	Isotope-Labeled Compounds CDK	Cancer
CDK2-IN-13-d₃ is the deuterium labeled CDK2-IN-13 (HY-W478102). CDK2-IN-13 (Compound 15) is a CDK2 inhibitor with an IC₅₀ of 12 μM. CDK2-IN-13 can be used in research of cancer .

HY-144810

CDK2-IN-8	CDK	Cancer
CDK2-IN-8 is a potent *CDK2* inhibitor with an IC₅₀ of 1.74 µM. CDK2-IN-8 shows antiproliferative activity. CDK2-IN-8 has the potential for the research of melanoma .

HY-160643

CDK2-IN-27	CDK	Cancer
CDK2-IN-27 (compound 1) is a potent *CDK2* inhibitor with IC₅₀ values of <10, >10-20 nM for CDK2/cyclin E1, CDK2/cyclin B1, respectively .

HY-144811

CDK2-IN-9	CDK Apoptosis	Cancer
CDK2-IN-9 is a potent *CDK2* inhibitor with an IC₅₀ of 0.63 µM. CDK2-IN-9 shows antiproliferative activity. CDK2-IN-9 induces apoptosis and cell cycle arrest at S and G2/M phase. CDK2-IN-9 has the potential for the research of melanoma .

HY-159805

CDK2-IN-31	CDK	Cancer
CDK2-IN-31 (compound I-125A) is a *CDK2* inhibitor. CDK2-IN-31 can be used in cancer research .

HY-151580

CDK2-IN-14	CDK	Cancer
CDK2-IN-14 (compound 4f) is a highly selective *CDK2* inhibitor. CDK2-IN-14 can be used in research of cancer .

HY-148651

CDK2-IN-15	CDK	Cardiovascular Disease Cancer
CDK2-IN-15 (Compound 19) is an inhibitor of *CDK2* with an IC₅₀ of 2.9 μM. CDK2-IN-15 can be used for cancer research .

HY-170897

CDK2-IN-40	CDK	Cancer
CDK2-IN-40 is a CDK2 (Cyclin dependent kinase 2) inhibitor, extracted from patent WO 2024/254245 A1 (Example 1). CDK2-IN-40 inhibits *CDK2*/Cyclin E1 with an IC₅₀ of ≤ 10 nM .

HY-169683

CDK2-IN-39	CDK	Cancer
CDK2-IN-39 (compound 4) is a *CDK2* inhibitor .

HY-163357

CDK2/MDM2-IN-1	CDK MDM-2/p53	Cancer
CDK2/MDM2-IN-1 (III-13) is a dual inhibitor of CDK2/MDM2 with an IC₅₀ value of 2.60 nM for CDK2. CDK2/MDM2-IN-1 has antitumor activity .

HY-E70674

CDK2/CycO Recombinant Human Active Protein Kinase	CDK	Cancer
CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycO Recombinant Human Active Protein Kinase is an ortholog of CDK2 .

HY-169910

CDK2 degrader 4	CDK	Cancer
CDK2 degrader 4 (compound 104) is a potent *CDK2* degrader. CDK2 degrader 4 has the potential for the research of cancer .

HY-139651

CDK2-IN-7	CDK	Cancer
CDK2-IN-7 is a *CDK2* inhibitor for researching cancer (IC₅₀ < 50 nM).

HY-160556

CDK2-IN-26	CDK	Cancer
CDK2-IN-26 (compound 9) is a potent inhibitor of CDK2 .

HY-178007

CDK2 degrader 8	CDK	Cancer
CDK2 degrader 8 (Compound1) is a *CDK2* degrader. CDK2 degrader 8 shows potential anti-tumor activity by targeting *CDK2. CDK2* degrader 8 can be used for the study of solid tumors (breast cancer, triple negative breast cancer, ovarian serous cystadenocarcinoma) and liquid tumors (diffuse large B-cell lymphoma, acute myelogenous leukemia) associated with abnormal *CDK2* function .

HY-170441

CDK2-IN-36	CDK	Cancer
CDK2-IN-36 (compound1) is a *CDK2* inhibitor with anticancer activity .

HY-151580S

CDK2-IN-14-d3	CDK	Cancer
CDK2-IN-14-d₃ is a potent and selective CDK2 inhibitor. CDK2-IN-14-d₃ can be used in research of cancer .

HY-E70672

CDK2/CycE1 Recombinant Human Active Protein Kinase	CDK	Cancer
CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycE1 Recombinant Human Active Protein Kinase is an ortholog of CDK2 .

HY-E70673

CDK2/CycE2 Recombinant Human Active Protein Kinase	CDK	Cancer
CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycE2 Recombinant Human Active Protein Kinase is an ortholog of CDK2 .

HY-E70671

CDK2/CycD1 Recombinant Human Active Protein Kinase	CDK	Cancer
CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycD1 Recombinant Human Active Protein Kinase is an ortholog of CDK2 .

HY-E70669

CDK2/CycA1 Recombinant Human Active Protein Kinase	CDK	Cancer
CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycA1 Recombinant Human Active Protein Kinase is an ortholog of CDK2 .

HY-E70670

CDK2/CycA2 Recombinant Human Active Protein Kinase	CDK	Cancer
CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycA2 Recombinant Human Active Protein Kinase is an ortholog of CDK2 .

HY-173203

CDK2-IN-43	CDK	Cancer
CDK2-IN-43 (Compound 3a) is a CDK2-cyclin E2 inhibitor with an IC₅₀ value of 6.0 nM. CDK2-IN-43 can be used in the research of the anti-cancer field .

HY-155441

CDK2-IN-20	CDK	Cancer
CDK2-IN-20 (compound 3b) is an inhibitor of *CDK2. CDK2-IN-20* has cytotoxicity on tumor cells presenting an IC₅₀ range of 5.52-17.09 µM. CDK2-IN-20 arrests the MCF-7 cell cycle at the S phase and induces apoptosis .

HY-155966

CDK2-IN-19	CDK	Cancer
CDK2-IN-19 (Compound 32) is a selective and orally active *CDK2* inhibitor (K_i: 0.18 nM). CDK2-IN-19 shows anticancer activity in mice bearing OVCAR3 tumors .

HY-176444B

*(S)-CDK2* degrader 6**	CDK Molecular Glues	Cancer
(S)-CDK2 degrader 6 (Compound 8) is the S-enantiomer of CDK2 degrader 6 (HY-176444). (S)-CDK2 degrader 6 is a selective *CDK2* molecular glue degrader with a DC₅₀ of 166.7 nM in 24 h. (S)-CDK2 degrader 6 can be used for breast cancer research .

HY-176444A

*(R)-CDK2* degrader 6**	CDK Molecular Glues	Cancer
(R)-CDK2 degrader 6 (Compound 7) is the R-enantiomer of CDK2 degrader 6 (HY-176444). (R)-CDK2 degrader 6 is a selective *CDK2* molecular glue degrader with a DC₅₀ of 27.0 nM in 24 h. (R)-CDK2 degrader 6 can be used for breast cancer research .

HY-150573

CDK2-IN-12	CDK Carbonic Anhydrase	Cancer
CDK2-IN-12 (compound 10b) is a potent *CDK2* inhibitor, with an IC₅₀ of 11.6 μM. CDK2-IN-12 inhibits hCA (carbonic anhydrase) isoforms I, II, IX and XII, with K_I values of 3534, 638.4, 44.3, and 48.8 nM. CDK2-IN-12 shows anticancer activity .

HY-176174S

CDK2-IN-46	Isotope-Labeled Compounds CDK	Cancer
CDK2-IN-46 (compound 5g) is a selective *CDK2* inhibitor with an IC₅₀ of 0.3 nM. CDK2-IN-46 has a selectivity of >200-fold for CDK1, CDK7, CDK9, CDK4, and CDK6. CDK2-IN-46 shows improves rat and cyno pharmacokinetic profiles .

HY-169246

CDK2-IN-32	CDK Apoptosis	Cancer
CDK2-IN-32 (Compound 5g) is a selective *CDK2* inhibitor with an IC₅₀ of 0.21 μM. CDK2-IN-32 shows cytotoxicity against Vero cells with an IC₅₀ of 28.52 μM .

HY-112460

CDK2-IN-3	CDK	Cancer
CDK2-IN-3 (compound 3) is a potent and selective *CDK2* inhibitor with an IC₅₀ of 60 nM .

HY-178112

CDK2-IN-47	CDK Apoptosis	Cancer
CDK2-IN-47 is a potent *CDK2* inhibitor with an IC₅₀ of 0.21 μM. CDK2-IN-47 exhibits outstanding anticancer activity against MCF-7, HCT-116, and MGC-803 cell lines. CDK2-IN-47 effectively induces G1 cell cycle arrest, retinoblastoma protein (Rb) dephosphorylation, and significant apoptosis. CDK2-IN-47 can be used for the studies of breast cancer, colorectal cancer and gastric cancer .

HY-172872

CDK2-IN-45	CDK Apoptosis	Cancer
CDK2-IN-45 (Compound 8f) is a CDK2 inhibitor (IC₅₀: 0.64 μM). CDK2-IN-45 inhibits the proliferation of DU-145 and PC-3 cell lines with IC₅₀ of 2.20 μM and 4.17 μM, respectively. CDK2-IN-45 induces G0/G1 cell cycle arrest and apoptosis. CDK2-IN-45 can be used in prostate cancer research .

HY-169912

CDK2 degrader 5	CDK	Cancer
CDK2 degrader 5 (compound 12) is a degrader for *CDK2, with the D_max* of >50% and ≤80% in HiBiT Assay. CDK2 degrader 5 plays an important role in cancer research .

HY-161291

CDK2-IN-25	CDK	Cancer
CDK2-IN-25 (compound 7e) is a CDK2 inhibitor with an IC₅₀ of 0.149 μM .

HY-168057

*PROTAC CDK2* Degrader-1**	PROTACs CDK	Cancer
PROTAC CDK2 Degrader-1 (Compound 41) is a PROTAC degrader for cyclin-dependent kinase 2 (CDK2). PROTAC CDK2 Degrader-1 inhibits the phosphorylation of RB protein in CDK2 dependent cell line OVCAR3 with an IC₅₀ of 100-500 nM .

HY-161463

CDK2-IN-28	CDK	Cancer
CDK2-IN-28 (compound 22) is a *CDK2* inhibitor with good selectivity and cellular effects against other CDKs. CDK2-IN-28 has anti-proliferative effects on MKN1 cells (EC50: 0.31 μM) .

HY-170442

CDK2-IN-37	CDK	Cancer
CDK2-IN-37 (COMPOUND 2) is a cyclin-dependent kinase *(CDK2)* inhibitor with anti-cancer activity .

HY-173224

CDK2/PIM1-IN-1	CDK Pim	Cancer
CDK2/PIM1-IN-1 is an inhibitor of *CDK2* (IC₅₀: 0.27 μM) and PIM1 (IC₅₀: 0.67 μM) kinases. CDK2/PIM1-IN-1 induces apoptosis and reduces tumor-promoting TNF-α expression. CDK2/PIM1-IN-1 has antitumor activity .

HY-155602

CDK2-IN-18	CDK	Cancer
CDK2-IN-18 (compound 8q) is a potent inhibitor of *CDK2/E* and CDK4/D1, with IC₅₀s of 8 nM and 46 nM, respectively. CDK2-IN-18 inhibits the proliferation of tumor cells .

HY-151573

*EGFR/CDK2-IN-1*	EGFR CDK	Cancer
EGFR/CDK2-IN-1 (Compound 3b) is an *EGFR/CDK2* inhibitor. EGFR/CDK2-IN-1 shows good cytotoxicity against MCF7 and HepG2 cells. EGFR/CDK2-IN-1 can be used in cancer research .

HY-173310

CDK2-IN-44	CDK	Cancer
CDK2-IN-44 (Compound 46) is an inhibitor of cyclin-dependent kinase 2 (CDK2). CDK2-IN-44 can effectively inhibit the proliferation of cancer cells and exert its activity in inhibiting cancer cell growth by arresting the cell cycle, promoting Apoptosis, and inducing cellular senescence. CDK2-IN-44 holds promise for use in the research of ovarian cancer and breast cancer .

HY-164827

CDK2 degrader 3	CDK	Cancer
CDK2 degrader 3 can selectively degrade *CDK2* and has anti-tumor activity .

HY-176444

CDK2 degrader 6	Molecular Glues CDK	Cancer
CDK2 degrader 6 (compound 6) is an orally active and potent CDK2 molecular glue degrader with a DC₅₀ of 46.5 nM. CDK2 degrader 6 can be used in the study of breast cancer .

HY-172153

CDK2-IN-41	CDK Reactive Oxygen Species (ROS) Apoptosis	Cancer
CDK2-IN-41 (Compound 7a) is a *CDK2* inhibitor that exerts anticancer activity by binding to *CDK2, thereby inhibiting the cell cycle, inducing cytotoxicity, promoting ROS* production, and triggering Apoptosis. CDK2-IN-41 exhibits an IC₅₀ of 10 µM against acute myeloid leukemia (AML) HL-60 cells. It holds potential for research in AML-related cancer therapy .

Cat. No.	Product Name	Target	Research Area

HY-P0235

*CDK2*	Peptides	Cancer
CDK2 is a member of the eukaryotic S/T protein kinase family and its function is to catalyze the phosphoryl transfer of ATP γ-phosphate to serine or threonine hydroxyl (denoted as S₀/T₀) in a protein substrate.

HY-P3730

Cdk2/Cyclin Inhibitory Peptide I	CDK	Cancer
Cdk2/Cyclin Inhibitory Peptide I (Tat-LFG), a *CDK2* inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner .

HY-P10324

TAT-p16 p16^INK4a peptide	Peptides	Cancer
TAT-p16 (p16INK4a peptide) is a peptide mimic of p16INK4a that can induce an early G phase cell cycle arrest in the absence of active cyclin E:Cdk2 complex .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6953

Garcinone D 3 Publications Verification	Xanthones Guttiferae Source classification Phenols Polyphenols Garcinia mangostana Linn. Plants	STAT Keap1-Nrf2 Reactive Oxygen Species (ROS)
Garcinone D is an activator of the STAT3/Cyclin D1 and Nrf2/HO-1 pathways, and an inhibitor of *CDK2/CyclinE1* (IC₅₀ for CDK2/CyclinE1 is 28.23 μM). Garcinone D promotes neural stem cell proliferation by activating STAT3 phosphorylation and Cyclin D1 expression and enhancing the Nrf2/HO-1 signaling pathway. In addition, Garcinone D blocks the tumor cell cycle by inhibiting CDK2/CyclinE1. Garcinone D can promote the proliferation of C17.2 neural stem cells and inhibit prostate and breast cancer .

HY-N5072

Desmethylglycitein 2 Publications Verification 4',6,7-Trihydroxyisoflavone	Flavonoids Classification of Application Fields Leguminosae Glycine max (L.) merr Source classification Phenols Polyphenols Plants Disease Research Fields Isoflavones Cancer	CDK PI3K PKC
Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced from Glycine max with antioxidant, and anti-cancer activities. Desmethylglycitein binds directly to CDK1 and *CDK2* in vivo, resulting in the suppresses CDK1 and CDK2 activity . Desmethylglycitein is a direct inhibitor of protein kinase C (PKC)α, against solar UV (sUV)-induced matrix matrix metalloproteinase 1 (MMP1) . Desmethylglycitein binds to PI3K in an ATP competitive manner in the cytosol, where it inhibits the activity of PI3K and downstream signaling cascades, leading to the suppression of adipogenesis in 3T3-L1 preadipocytes .

HY-N1465

Aristolochic acid D Aristolochic acid-IVa	Monophenols other families Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Plants Disease Research Fields Cancer	Phosphodiesterase (PDE) CDK Interleukin Related
Aristolochic acid D (Aristolochic acid-IVa) is an orally active PDE2 (IC₅₀: 4.673 μM) and *CDK2* (IC₅₀: 25 μM) inhibitor that can be isolated from Aristolochia indica L. Aristolochic acid D exhibits anti-inflammatory activity and is non-carcinogenic and non-nephrotoxic. Aristolochic acid D can be used in the research of inflammation and tumor-related diseases .

HY-18981

Decursin 1 Publications Verification (+)-Decursin	Classification of Application Fields Source classification Coumarins Phenylpropanoids Umbelliferae Plants Inflammation/Immunology Disease Research Fields Echinacea angustifolia DC.	PKC Apoptosis CXCR
Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities .

HY-N3389

Licoisoflavone A 1 Publications Verification	Flavonoids Classification of Application Fields Leguminosae Source classification Phenols Polyphenols Metabolic Disease Plants Glycyrrhiza uralensis Fisch. Disease Research Fields Isoflavones	SARS-CoV Sirtuin CDK Apoptosis
Licoisoflavone A is an orally active isoflavone. Licoisoflavone A inhibits proliferation, induces apoptosis, and causes G1/S phase arrest in colorectal cancer (CRC) cells. Licoisoflavone A inhibits the *CDK2-Cyclin* E1 axis. Licoisoflavone A inhibits lipid peroxidation with an IC₅₀ of 7.2 μM. Licoisoflavone A shows a dose-dependent inhibition effect on SARS-CoV-2 infection. Licoisoflavone A exhibits significant anti-tumor efficacy in mice bearing CT26 cell subcutaneous xenografts. Licoisoflavone A can be used for the study of colorectal cancer and SARS-CoV-2 infection .

HY-W019806

Lacto-N-fucopentaose I LNFP I	Infection Natural Products Polysaccharides Classification of Application Fields Animals Inflammation/Immunology Disease Research Fields Saccharides	Endogenous Metabolite CDK Reactive Oxygen Species (ROS) Apoptosis Enterovirus Bacterial
Lacto-N-fucopentaose I (LNFPI) is a human milk oligosaccharide (HMO), possessing antiviral and antibacterial activity. Lacto-N-fucopentaose I can reduce capsid protein VP1 to block virus adsorption, promote *CDK2* and reduce cyclin E to recover cell cycle S phase block. Lacto-N-fucopentaose I inhibits ROS production and apoptosis in virus-infected cells. Lacto-N-fucopentaose I can also regulate intestinal microbiota to affect immune system development .

HY-N7045

Isosilybin B 2 Publications Verification	Flavanonols Flavonoids Glycine soya Classification of Application Fields Source classification Phenols Polyphenols Cyamopsis tetragonoloba (L.) Taub. Plants Compositae Disease Research Fields Cancer	Androgen Receptor Apoptosis CDK Caspase PSMA
Isosilybin B is a flavonolignan. Isosilybin B can be isolated from Silybum marianum. Isosilybin B can regulate cell cycle-related proteins (e.g., reduce cyclins (D3, D1, A, E), Cdk4, *Cdk2, Cdc25A), and activate Caspases* (Caspase-9 and Caspase-3). Isosilybin B can promote Apoptosis, reduce androgen receptor (AR) and PSA. Isosilybin B has anticancer activity against prostate cancer .

HY-149436

CDK2/Bcl2-IN-1	Terpenoids Zygophyllaceae Source classification Diterpenoids Plants Zygophyllum album L.f.	CDK
CDK2/Bcl2-IN-1 (compound 1), a saponin and a CDK-2 inhibitor (IC₅₀=117.6 nM) with promising cytotoxicity against cancer cells. CDK2/Bcl2-IN-1 also inhibits Bcl-2, and induces apoptosis in A549 lung cancer cells .

HY-N6953R

Garcinone D (Standard)	Xanthones Guttiferae Source classification Phenols Polyphenols Garcinia mangostana Linn. Plants	Reference Standards STAT Keap1-Nrf2 Reactive Oxygen Species (ROS)
Garcinone D (Standard) is the analytical standard of Garcinone D (HY-N6953). This product is intended for research and analytical applications. Garcinone D is an activator of the STAT3/Cyclin D1 and Nrf2/HO-1 pathways, and an inhibitor of *CDK2/CyclinE1* (IC₅₀ for CDK2/CyclinE1 is 28.23 μM). Garcinone D promotes neural stem cell proliferation by activating STAT3 phosphorylation and Cyclin D1 expression and enhancing the Nrf2/HO-1 signaling pathway. In addition, Garcinone D blocks the tumor cell cycle by inhibiting CDK2/CyclinE1. Garcinone D can promote the proliferation of C17.2 neural stem cells and inhibit prostate and breast cancer .

HY-N5072R

Desmethylglycitein (Standard)	Flavonoids Leguminosae Glycine max (L.) merr Source classification Phenols Polyphenols Plants Isoflavones	CDK PI3K PKC
Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced from Glycine max with antioxidant, and anti-cancer activities. Desmethylglycitein binds directly to CDK1 and CDK2 in vivo, resulting in the suppresses CDK1 and CDK2 activity . Desmethylglycitein is a direct inhibitor of protein kinase C (PKC)α, against solar UV (sUV)-induced matrix matrix metalloproteinase 1 (MMP1) . Desmethylglycitein binds to PI3K in an ATP competitive manner in the cytosol, where it inhibits the activity of PI3K and downstream signaling cascades, leading to the suppression of adipogenesis in 3T3-L1 preadipocytes .

HY-N7364

(E)-β-Farnesene trans-β-Farnesene	Infection Cannabis sativa L Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Moraceae Disease Research Fields	Fungal CDK
(E)-β-Farnesene (trans-β-Farnesene) is an aphid alarm pheromone, which can be found in Phlomis aurea Decne essential oil. (E)-β-Farnesene shows good binding score with a value of -30.64 kcal/mol to the CDK2 receptor. (E)-β-Farnesene also exhibits good affinity to odorant-binding protein 3 (OBP3). (E)-β-Farnesene can be used as a feeding stimulant for the sand fly Lutzomyia longipalpis .

HY-18981R

Decursin (Standard) (+)-Decursin (Standard)	Source classification Coumarins Phenylpropanoids Umbelliferae Plants Echinacea angustifolia DC.	Reference Standards PKC Apoptosis CXCR
Decursin (Standard) is the analytical standard of Decursin. This product is intended for research and analytical applications. Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities [4].

HY-N1465R

Aristolochic acid D (Standard) Aristolochic acid-IVa (Standard)	Monophenols other families Ketones, Aldehydes, Acids Source classification Phenols Plants	Reference Standards CDK Phosphodiesterase (PDE) Interleukin Related
Aristolochic acid D (Standard) (Aristolochic acid-IVa (Standard)) is the analytical standard of Aristolochic acid D (HY-N1465). This product is intended for research and analytical applications. Aristolochic acid D (Aristolochic acid-IVa) is an orally active PDE2 (IC₅₀: 4.673 μM) and *CDK2* (IC₅₀: 25 μM) inhibitor that can be isolated from Aristolochia indica L. Aristolochic acid D exhibits anti-inflammatory activity and is non-carcinogenic and non-nephrotoxic. Aristolochic acid D can be used in the research of inflammation and tumor-related diseases .

HY-N7045R

Isosilybin B (Standard)	Flavanonols Flavonoids Glycine soya Source classification Phenols Polyphenols Cyamopsis tetragonoloba (L.) Taub. Plants Compositae	Reference Standards Androgen Receptor Apoptosis CDK Caspase PSMA
Isosilybin B (Standard) is the analytical standard of Isosilybin B (HY-N7045). This product is intended for research and analytical applications. Isosilybin B is a flavonolignan. Isosilybin B can be isolated from Silybum marianum. Isosilybin B can regulate cell cycle-related proteins (e.g., reduce cyclins (D3, D1, A, E), Cdk4, *Cdk2, Cdc25A), and activate Caspases* (Caspase-9 and Caspase-3). Isosilybin B can promote Apoptosis, reduce androgen receptor (AR) and PSA. Isosilybin B has anticancer activity against prostate cancer .

HY-W097625

6-Methoxyflavone	Flavonoids Flavones Thymelaeaceae Source classification Plants Pimelea simplex F.Muell.	Toll-like Receptor (TLR) MyD88 p38 MAPK NF-κB Heme Oxygenase (HO)
6-Methoxyflavone is an orally active methoxyflavone. 6-Methoxyflavone suppresses neuroinflammation in microglia through the inhibition of TLR4/MyD88/p38 MAPK/NF-κB dependent pathways and the activation of HO-1/NQO-1 signaling. 6-Methoxyflavone induces S-phase arrest through the *CCNA2/CDK2/p21CIP*1 signaling pathway in HeLa cells. 6-Methoxyflavone inhibits NFAT Translocation into the nucleus and suppresses T cell activation. 6-Methoxyflavone partially restores chronic ethanol-induced behavioral deficits in mice. 6-Methoxyflavone antagonizes chronic constriction injury and diabetes associated neuropathic nociception expression. 6-Methoxyflavone can be used for the study of cancer, inflammation and neurological diseases .

HY-N8146

Bruceantinol	Infection Triterpenes Simaroubaceae Classification of Application Fields Brucea antidysenterica J.F.Mill. Terpenoids Source classification Plants Disease Research Fields Brucea javanica (L.) Merr. Cancer	STAT Bcl-2 Family Ser/Thr Kinase Survivin c-Myc Apoptosis Necroptosis CDK
Bruceantinol is a quassinoid that can be isolated from Brucea javanica, inhibits pepper mottle virus (PepMoV) in pepper. Bruceantinol is a STAT3 inhibitor demonstrating potent antitumor activity in in vitro and in vivo human colorectal cancer (CRC) models. Bruceantinol has potent anti-leukemic activity. Bruceantinol strongly inhibits STAT3 DNA-binding ability (IC₅₀ = 2.4 pM), blocks the constitutive and IL-6-induced STAT3 activation, and suppresses transcription of MCL-1, PTTG1, survivin and c-Myc. Bruceantinol binds with *CDK2/4/6* to facilitate protein degradation through proteasome pathway. Bruceantinol can dose- and time-dependently reduces the cell growth, impede cell proliferation, disrupts the cell cycle, and induces necrosis in MCF-7 cells and apoptosis in MDA-MB-231 cells .

Cat. No.	Product Name	Chemical Structure

HY-W478102S

CDK2-IN-13-d3
CDK2-IN-13-d₃ is the deuterium labeled CDK2-IN-13 (HY-W478102). CDK2-IN-13 (Compound 15) is a CDK2 inhibitor with an IC₅₀ of 12 μM. CDK2-IN-13 can be used in research of cancer .

HY-151580S

CDK2-IN-14-d3
CDK2-IN-14-d₃ is a potent and selective CDK2 inhibitor. CDK2-IN-14-d₃ can be used in research of cancer .

HY-176174S

CDK2-IN-46
CDK2-IN-46 (compound 5g) is a selective *CDK2* inhibitor with an IC₅₀ of 0.3 nM. CDK2-IN-46 has a selectivity of >200-fold for CDK1, CDK7, CDK9, CDK4, and CDK6. CDK2-IN-46 shows improves rat and cyno pharmacokinetic profiles .

HY-P10324

TAT-p16
TAT-p16 (p16INK4a peptide) is a peptide mimic of p16INK4a that can induce an early G phase cell cycle arrest in the absence of active cyclin E:Cdk2 complex .

HY-N7364S

(E)-β-Farnesene-d6

(E)-β-Farnesene-d₆ is deuterated labeled (E)-β-Farnesene (HY-N7364). (E)-β-Farnesene (trans-β-Farnesene) is an aphid alarm pheromone, which can be found in Phlomis aurea Decne essential oil. (E)-β-Farnesene shows good binding score with a value of -30.64 kcal/mol to the CDK2 receptor. (E)-β-Farnesene also exhibits good affinity to odorant-binding protein 3 (OBP3). (E)-β-Farnesene can be used as a feeding stimulant for the sand fly Lutzomyia longipalpis .

Cat. No.	Product Name		Classification

HY-122609

XO44 PF-6808472		Alkynes
XO44 (PF-6808472) is a broad-spectrum covalent kinase probe. XO44 can bind in *CDK2 and CDK1. XO44 also labels CDK4* proteins in cells .

HY-148213

CDK2/4/6-IN-1		Alkynes
CDK2/4/6-IN-1(example 29) is a *CDK2/4/6* inhibitor with IC₅₀ values of 2.5, 23.7 and 44.3 nM for CDK2, CDK4 and CDK6, respectively. CDK2/4/6-IN-1 can be used in cancer research . CDK2/4/6-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks